ME Therapeutics Holdings Inc. (CSE:METX)

Canada flag Canada · Delayed Price · Currency is CAD
9.00
0.00 (0.00%)
Apr 17, 2025, 4:00 PM EDT
141.94%
Market Cap 235.71M
Revenue (ttm) n/a
Net Income (ttm) -1.31M
Shares Out 26.19M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 61
Open 9.00
Previous Close 9.00
Day's Range 9.00 - 9.00
52-Week Range 0.75 - 11.00
Beta n/a
RSI 47.89
Earnings Date Jun 23, 2025

About ME Therapeutics Holdings

ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno‐oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Country Canada
Stock Exchange Canadian Securities Exchange
Ticker Symbol METX
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.